

## PATIENT INFORMATION

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_ Sex: M / F Ht: \_\_\_\_\_ Wt: \_\_\_\_\_ lbs / kg  
 Primary Language: \_\_\_\_\_ Allergies: \_\_\_\_\_  
 Patient Preferred Location: \_\_\_\_\_

<ICD 10 CODE REQUIRED>

## DIAGNOSIS & CLINICAL INFORMATION

**ICD 10 Code (PROVIDE COMPLETE CODE)**

- |   |  |   |
|---|--|---|
| <input type="checkbox"/> K50.0 _____ Crohn's Disease, Small Intestine         | <input type="checkbox"/> L40.0 Psoriasis Vulgaris (Plaque Psoriasis) | <input type="checkbox"/> M05.0 _____ Felty's Syndrome                           |
| <input type="checkbox"/> K50.1 _____ Crohn's Disease, Large Intestine         | <input type="checkbox"/> L40.50 Arthropathic Psoriasis               | <input type="checkbox"/> M05. _____ Rheumatoid Arthritis, w/ Rheumatoid Factor  |
| <input type="checkbox"/> K50.8 _____ Crohn's Disease, Small & Large Intestine | <input type="checkbox"/> L40.52 Psoriatic Arthritis                  | <input type="checkbox"/> M06. _____ Rheumatoid Arthritis, w/o Rheumatoid Factor |
| <input type="checkbox"/> K50.9 _____ Crohn's Disease, Unspecified             | <input type="checkbox"/> L40.59 Other Psoriatic Arthropathy          | <input type="checkbox"/> M45. _____ Ankylosing Spondylitis                      |
|   | <input type="checkbox"/> L40.9 Psoriasis, Unspecified                | <input type="checkbox"/> M46.8 _____ Non-Radiographic Axial Spondylarthritis    |

**REQUIRED: Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.**  
**LAB RESULTS: Include Negative Hepatitis B within 3 years & Negative TB within 12 months.**

## PRESCRIPTION

**Lab Orders**

Required: Negative TB, annually

**+Medix Infusion will draw maintenance labs unless otherwise directed by Referring Provider.**

**Cimzia (certolizumab pegol)**

Loading Dose:

- SubQ:** Inject 400 mg at weeks 0, 2, and 4

Maintenance: (SELECT ONE)

- SubQ:** Inject 200 mg every 2 weeks for one year  
 **SubQ:** Inject 400 mg every 4 weeks for one year

In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reaction protocol.

**Post Treatment Observations:** The patient is observed for 30 minutes following the first injection.

Comments: \_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_

## PRESCRIBER INFORMATION

Prescriber Name: \_\_\_\_\_ *Signature:* \_\_\_\_\_

Date: \_\_\_\_\_ NPI #: \_\_\_\_\_ Specialty: \_\_\_\_\_

Supervising Physician: \_\_\_\_\_ (If Applicable)

Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Contact Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Email: \_\_\_\_\_